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Cyclophilin B (CypB) is a member of the immunophilin family and intracellular chaperone. It pre-
dominantly localizes to the ER, but also contains a nuclear localization signal and is secreted from cells.
CypB has been shown to interact with the Gag protein of human immunodeﬁciency type 1 (HIV-1).
Several proteomic and genetic studies identiﬁed it as a potential factor involved in HIV replication.
Herein, we show that over-expression of CypB enhances HIV infection by increasing nuclear import of
viral DNA. This enhancement was unaffected by cyclosporine treatment and requires the N-terminus of
the protein. The N-terminus contains an ER leader sequence, putative nuclear localization signal, and is
required for secretion. Deletion of the N-terminus resulted in mislocalization from the ER and sup-
pression of HIV infection. Passive transfer experiments showed that secreted CypB did not impact HIV
infection. Combined, these experiments show that intracellular CypB modulates a pathway of HIV
nuclear import.
& 2015 Elsevier Inc. All rights reserved.Introduction
Human Immunodeﬁciency Virus type 1 (HIV-1) is the causative
agent of Acquired Immune Deﬁciency Syndrome (AIDS) and has
remained a global health problem for over thirty years. HIV-1 is
retrovirus which primarily targets the CD4þ T-cells of the
immune system. The HIV-1 genome consists of 9 open reading
frames encoding only 15 viral proteins (Frankel and Young, 1998).
As an obligate intracellular parasite, HIV must utilize host proteins
and pathways for effective replication while evading the innate
and acquired immune responses. Thus far, approximately 3500
human proteins have been found to participate in HIV-1 replica-
tion in some capacity (NCBI HIV Interaction Database; (Ako-Adjei
et al., 2014)). A major challenge is identifying the subset of these
interaction partners that can be targeted as cell-based viral inhi-
bitors. This necessitates characterizing normal protein function as
well as deciphering how a factor interacts with HIV and impacts
viral replication.
Cyclophilin B (CypB) was identiﬁed in a number of proteomic
investigations performed by our laboratory, including: a character-
ization of the interactome of Matrix and Integrase, a study of partially
puriﬁed preintegration complexes, and a study of the nuclei of HIV-
infected T-cells ((DeBoer et al., 2014; Schweitzer et al., 2013, 2012),Microbiology & Immunology,
E 68178, USA.
. Belshan).unpubublished data). Additionally, CypB was shown to be signiﬁcantly
upregulated in the nuclei of HIV-infected monocyte-derived macro-
phages (Haverland et al., 2014) and identiﬁed as an HIV-dependency
factor (Brass et al., 2008). CypB, also known as peptidyl prolyl iso-
merase B (PPIB), is a member of the cyclophilin family of immuno-
philins. CypA, the initial member of this family, was identiﬁed by its
ability to bind the immunosuppressant cyclosporine A (CsA). CsA
binding to CypA inhibits calcineurin and prevents dephosphorylation
and nuclear translocation of the transcription factor NFAT (Friedman
and Weissman, 1991; Liu et al., 1991; Schreiber and Crabtree, 1992).
Cyclophilins contain a peptidyl prolyl isomerase (PPI) domain that
functions to lower the rotational energy barrier in prolyl imide bonds.
The core domain of CypB (aa 48-143) has 80% homology with CypA
and contains both the PPI and CsA binding region (Fig. 1). However,
the functions of CypA and CypB are distinct. CypA is primarily a
cytoplasmic protein, whereas CypB is widely distributed and present
in the cytoplasm, nucleus, ER/golgi and plasma membrane (Price
et al., 1994). CypB contains a N-terminal hydrophobic leader con-
sistent with an endoplasmic reticulum (ER) signal sequence, as well
as a C-terminal ER retention signal (Arber et al., 1992), where it may
act as a chaperone for exported proteins (Price et al., 1994). ER
localization results in approximately 50% of CypB being secreted from
the cell (Caroni et al., 1991). In addition, CypB associates with col-
lagen, is required for its intracellular transport, and correct collagen
ﬁbril formation (Choi et al., 2009; Smith et al., 1995). CsA treatment
reduces the isomerization activity of CypB (Spik et al., 1991), blocks
collagen binding (Smith et al., 1995), and causes an increase in CypB
Fig. 1. Domain structure of CypB and the deletion mutants used in this study. The
approximate location of previously described domains are shown including the
core domain conserved between CypB and CypA.
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perone for CAML (von Bülow and Bram, 1997), IRF-3 (Obata et al.,
2005), and Prolactin (PRL) (Rycyzyn et al., 2000). Knock-down of
CypB reduces virus induced phosphorylation of IRF-3 and its sub-
sequent induction of interferon-β. CypB mediates nuclear retrotran-
sport of PRL following receptor interaction and internalization. The
intranuclear PRL–CypB complex activates Stat5-mediated gene
expression (Rycyzyn and Clevenger, 2002).
CypA is an established HIV factor and its interaction with viral
cores is necessary for capsid stabilization, proper uncoating, pro-
tection of viral cores from cellular restriction factors (Sayah et al.,
2004), and efﬁcient HIV replication is inhibited by CsA in vitro
(Aiken, 1998; Franke and Luban, 1996; Karpas et al., 1992;
Wainberg et al., 1988). Both CypA and CypB have been found to
bind HIV-1 Gag (Franke et al., 1994; Luban et al., 1993). The CypA-
HIV-1 interaction with Gag occurs at Gag proline 222. An alanine
substitution at this position ablates CypA binding and blocks
replication. CypB appears to interact in an independent manner
with Gag. It binds Gag with stronger afﬁnity due to its hydro-
phobic N-terminal ER signal sequence and its binding is less sen-
sitive to disruption by CsA compared to CypA (Luban et al., 1993).
Moreover, mutation of proline 222 does not block the interaction
of CypB and Gag (Franke et al., 1994). Initial studies reported that
only CypA is incorporated into virions (Franke et al., 1994; Thali
et al., 1994); however, a later study detected CypB in virions by
mass spectrometry (Chertova et al., 2006). CypB is also essential
for successful infection of multiple viruses, including hepatitis C
virus (HCV) (Watashi et al., 2005), Japanese encephalitis virus
(JEV) (Kambara et al., 2011), and human papillomavirus type 16
(HPV16) (Bienkowska-Haba et al., 2009).
Given the repeated identiﬁcation of CypB in HIV proteomic stu-
dies, we hypothesized that it played an important role in HIV repli-
cation. We were not able to knock-down CypB by RNA interference in
293T cells so alternate methods were explored. We discovered that
ectopic expression of CypB enhances HIV infection at the step of
nuclear import of the viral DNA. This enhancement is distinct from
CypA and the N-terminus of CypB is necessary for the effect. Deletion
of the leader sequence of CypB alters localization of the CypB and
hinders its secretion from the cell. However, media transfer experi-
ments suggested that secreted CypB does not play a major role in
increasing infection. Finally, inhibition of the Stat5 pathway does not
interfere with the enhancement. Combined, these results demon-
strate that CypB modulates HIV nuclear import.Fig. 2. CypB expression in primary PBMCs. (A) Infection of donor-derived lym-
phocytes. Cells were activated with PHA and infected with NLX virus. Virus repli-
cation was monitored by RT assay of cell supernatants using an in vitro [32P]dTTP
incorporation assay. Results presented are representative of triplicate experiments.
(B) Unstimulated, PHA-stimulated, and PHA-stimulated infected PBMCs were
fractionated into cytosolic (Cyt), membrane/organelle (Mem), nuclear (Nu), and
cytoskeletal/insoluble (In) fractions. Equivalent amounts of each fraction was
separated by SDS-PAGE and immunoblotted for CypB. Example blots of the controls
used for fraction integrity and protein concentration are shown in bottom three
panels.Results
CypB is upregulated in activated PBMCs during HIV infection
CypB has been identiﬁed in a number of proteomic studies of
HIV infected cells and puriﬁed virions (Chertova et al., 2006;
Haverland et al., 2014; Schweitzer et al., 2013), including a recentstudy in which we observed that it was increased in the nuclei of
HIV infected Jurkat T-cells (DeBoer et al., 2014). To extend those
observations we investigated the subcellular expression of CypB in
primary peripheral blood mononuclear cells (PBMCs) during HIV
infection (Fig. 2). Unstimulated, PHA-stimulated, and HIV-1
infected cells were fractionated into cytosolic, membrane/orga-
nelle, nuclear, and cytoskeletal/insoluble fractions using a com-
mercially available kit. Infections were monitored by reverse
transcriptase assay of cell supernatants and peaked at 6 dpi
(Fig. 2A). In all experiments the integrity of subcellular fractions
was monitored by detection of GAPDH (cytosol), ERGIC (mem-
brane/organelle), and TOPO IIa (nuclei) (Fig. 2B, bottom blots). The
subcellular distribution of CypB was dynamic. Unstimulated
PBMCs expressed CypB primarily in the membrane/organelle
fraction. Upon stimulation with PHA, CypB was also detected in
J. DeBoer et al. / Virology 489 (2016) 282–291284the nuclear fractions of cells. Infection with HIV-1 also correlated
with the expression of CypB in both the membrane and nuclear
fractions. Consistent with a loss of cell viability after the peak of
infection there was slightly less CypB detected in both fractions at
7 dpi compared to 3 dpi. These results support the hypothesis that
CypB is involved in HIV replication.CypB enhances HIV-1 infection
To study the potential role of CypB in HIV infection, we initially
attempted depletion studies using RNAi. Although previously
identiﬁed in a siRNA screen (Brass et al., 2008), our efforts to
knock-down CypB expression using small interfering or short
hairpin RNAs were unsuccessful. Therefore we moved to gain-of-
function/over-expression studies to test for its impact on HIV
infection. To do this we primed 293T cells with increasing amounts
of a FLAG-tagged CypB expression vector 24 h prior to infection
with a VSVg-pseudotyped HIV luciferase reporter virus (HIV-Luc).
As shown in Fig. 3, increased expression of CypB enhanced the
infection of HIV in a dose-dependent manner. Notably, over-
expression of FLAG-tagged CypB did not appear to affect endo-
genous CypB expression (Fig. 3, CypB blot). To assess if this effect
was non-speciﬁc toward retroviruses, we performed parallel
experiments with a VSVg-psuedotyped murine leukemia virus
luciferase reporter virus (MLV-Luc). Increased expression of CypB
did not alter MLV infection, indicating that CypB did not have a
general effect on retrovirus transduction.Fig. 3. Over-expression of CypB enhances HIV-1 infection. Cells were transfected
with increasing amounts of CypB balanced with empty vector control plasmid. The
following day, cells were infected with either a VSVg-pseudotyped HIV-Luc or MLV-
Luc reporter virus. At 48 hpi, cells were harvested and infection quantiﬁed by Luc
assay which was normalized to total protein concentration. Results are normalized
and statistics compared to control cells transfected with empty vector alone
(*po0.005 and **po0.0005 by two-tailed t-test). Cell lysates were blotted for
transfected (FLAG) and endogenous CypB expression; and GAPDH was used as
loading control (bottom panels). Data shown is representative of three independent
experiments with triplicate infections. Error bars in this and all other ﬁgures
represent standard error of the mean.The mechanism of CypB infection enhancement is distinct from that of
CypA
Many studies have demonstrated a requirement for the inter-
action of CypA with HIV Gag for efﬁcient HIV infection. Although
CypB contains distinct N- and C-termini, both CypA and CypB bind
HIV-1 Gag (Luban et al., 1993), and share a core domain that is
80% homologous (Fig. 1). To investigate if CypB enhancement
was mediated through a mechanism analogous to CypA, infection
assays were conducted under conditions of increased CypA
expression. Over-expression of CypA did not result in any sig-
niﬁcant enhancement in HIV infection (Fig. 4A). This result sug-
gested that CypB potentiates HIV infection through a mechanism
distinct from that of CypA.
CsA binds to and inhibits the peptidyl prolyl isomerase (PPI)
activity of both CypA and CypB, and when bound to CypA inhibits
calcineurin function (Friedman and Weissman, 1991; Liu et al.,
1991; Schreiber and Crabtree, 1992). CsA treatment disrupts the
interaction of CypA and Gag leading to inhibition of HIV infection
in vitro (Aiken, 1998; Franke and Luban, 1996; Karpas et al., 1992;
Wainberg et al., 1988). To further explore the dichotomous results
of CypA and CypB over-expression, we tested whether cyclospor-
ine A (CsA) would antagonize the ability of CypB to enhance HIV
infection. The over-expression experiments were repeated with
cells treated with 5 mM CsA (Fig. 4B). As predicted from previous
studies, CsA partially inhibited HIV infection in mock transfected
cells. Moreover, this amount of CsA still inhibited infection when
CypA was overexpressed. Immunoblot analyses of Cyps revealed
that CsA substantially reduced the intracellular expression of both
endogenous CypB in 293T cells (Fig. 4B, CypB blot, (þ) lanes),
although it did not appear to affect CypA expression. The loss of
CypB correlated with increased secretion of CypB in to the media
as previously reported (Fig. 4C; (Price et al., 1994)). CsA treatment
did not affect the ability of exogenous CypB to potentiate HIV
infection. Moreover, CsA did not substantially reduce HIV infection
in CypB transfected cells despite slightly reducing the intracellular
levels of the transfected protein. These results demonstrated that
the CsA binding domain of CypB was not required for its ability to
enhance HIV infection and conﬁrmed that the ability of CypB to
potentiate infection was unrelated to the role of CypA in HIV
replication.
CypB increases nuclear import of HIV DNA
To determine how CypB mechanistically enhances HIV infec-
tion, we analyzed the early steps of HIV infection using real-time
PCR to quantify viral DNA species. In addition to over-expressing
CypB, we also included the following controls: Mock transfected
cells, cells infected with heat-inactivated virus, and cells trans-
fected with CypB Δ40, a mutant that does not potentiate infection
(see below). Late RT product accumulation was analyzed at 24 hpi
using gag-speciﬁc primers and normalized to the level of mito-
chondrial DNA as an internal control (Fig. 5A). Over-expression of
CypB did not alter the total amount of late RT products in com-
parison with either mock-transfected cells or those over-
expressing the Δ40 mutant. A similar result was found when we
quantiﬁed early RT products (- strand, strong stop DNA; data not
shown). This indicated that CypB did not enhance steps prior to,
and through reverse transcription. The import of viral DNA into
the nuclei of cells was assessed by quantifying 2-LTR circle accu-
mulation. The levels of 2-LTR circles were normalized to the levels
of late RT products to account for differences in the magnitude of
infection. As shown in Fig. 5B, the level of 2-LTR circles was higher
in cells over-expressing CypB compared to the mock-transfected
cells. The amount of 2-LTR circles was also slightly decreased in
the Δ40 transfected cells. To conﬁrm the increase in nuclear
Fig. 4. The effect of CypB over-expression is distinct from CypA. (A) Over-expression studies of CypA. Experiments were performed as described in Fig. 1 using a FLAG-tagged
CypA expression vector. Results are normalized to results from cells transfected with an empty vector. (B) CsA does not abrogate the ability of CypB to enhance infection. Cells
were pretransfected for 24 h with empty vector, CypA, or CypB then pretreated with CsA 2 h prior to infection with HIV-Luc VSVg. Cells were harvested and Luc activity
measured to quantify infection (normalized to total protein). Presented results are normalized to control DMSO treated cells; *po0.01 by two-tailed t-test. Cell lysates were
blotted for CypB and CypA expression using antibodies as indicated. GAPDH was used as loading control (bottom panels). (C) CsA induction of CypB secretion. 293T cells were
treated with indicated concentrations of CsA for 48 h. Media and cell lysates were collected and the levels of CypB detected by immunoblot. Actin was detected as a loading
control.
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viral DNA integrated in the genome of cells using an established
alu-based nested PCR assay (Brussel and Sonigo, 2003). Consistent
with the nuclear import/2-LTR data, the amount of integrated viral
DNA was higher in cells over-expressing CypB (Fig. 5C). Moreover,
cells expressing the Δ40 mutant had reduced levels of integrated
viral DNA. Combined, the 2-LTR and integrated viral DNA data
suggest that the over-expression of CypB enhances infection by
increasing the nuclear import of the viral DNA.
The N-terminus of CypB is necessary to enhance HIV-1 infection
The CypA data suggested that a region outside the core domain
of CypB was responsible for promoting HIV infection. To map the
domain(s) of CypB that were required for the enhancement effect,
we constructed a series of deletion mutants, as well as a PPI-
inactive mutant (PPIm; Fig. 1). Similar to the parental construct, all
the mutants were created with a C-terminal FLAG epitope to
support uniform detection. The ability of each mutant to affect HIV
infection was assessed under conditions of over-expression as in
previous experiments (Fig. 6A). Consistent with the CsA experi-
ments, disruption of the PPI motif did not affect the ability of CypB
to augment HIV infection. Deletion of the C-terminus (Δ206) was
also indistinguishable from WT CypB. In contrast, N-terminal
deletions reduced or eliminated the ability of CypB to potentiate
infection. Only theΔ5 mutant retained partial capacity to increase
infection. Consistent with the viral DNA analysis, the expression of
two larger N-terminal deletion mutants (Δ33 or Δ40) caused a
slight reduction of infection compared to mock-transfected cells.
Control immunoblots showed that all the mutants expressed(lower panels), although mutation of the PPI domain or deletion of
the C-terminus at amino acid 206 appeared to enhance the
expression of a larger isoform of the protein, which may be the
uncleaved or glycosylated form of CypB (Spik et al., 1991). This
isoform was not present in cells transfected with the Δ33 or Δ40
mutants. Finally, MTT assays showed that over-expression of CypB
and the derivative mutants did not impact overall health of the
cells (Fig. 6B).
Deletion of the N-terminus alters CypB localization
The N-terminus of CypB contains an ER signal sequence, a
putative nuclear localization signal (NLS), and is necessary for the
secretion of CypB (Rycyzyn et al., 2000). To assess the effect the
deletions had on the intracellular localization of CypB we per-
formed immunoﬂuorescence assays on cells transfected with the
different CypB deletion mutants (Fig. 7). Wild-type CypB showed
strong perinuclear localization typically with one distinct foci of
ﬂuorescence. The Δ5 mutant exhibited less perinuclear staining
than full-length CypB, but maintained distinct foci of ﬂuorescence
near the nuclei of cells. In contrast, theΔ10 mutant showed strong
perinuclear staining, but less distinct foci. Both the Δ33 and Δ40
mutants displayed diffuse cellular localization losing both the
perinuclear localization and distinct foci. The Δ206 C-terminal
mutant show staining similar to wild-type CypB and the PPI
mutant maintained generally perinuclear staining but with more
cytoplasmic punctae compared to wild-type CypB. Overall, all the
N-terminal deletions except Δ5 appear to distinctly perturb the
localization of CypB correlating with a loss of enhancement.
Combined, these results show that the mutants that lost the ability
Fig. 5. CypB increases nuclear import of HIV. In all experiments 293T cells were
transfected with either CypB or the Δ40 mutant and infected the following day
with NLXþVSVg. (A) For Late RT experiments extrachromosomal DNA was isolated
at 24 hpi. Late RT products quantiﬁed by qPCR using gag-speciﬁc primers. Levels
were normalized for DNA isolation efﬁciency by quantiﬁcation of mitochondrial
DNA (mtDNA) levels by qPCR. (B) 2-LTR circles were quantiﬁed from samples
harvested at 48 hpi. To account for infection efﬁciency, the levels of 2-LTR circles
were normalized to the level of late RT DNA in each sample (which was normalized
to mtDNA level). (C) Measurement of integrated viral DNA. Chromosomal DNA was
isolated at 48 hpi and integrated viral DNA measured by an alu-based nested qPCR
as outlined in Methods. Mock transfected and cells infected with heat inactivated
(HI) virus were used as controls in all experiments. Data presented in A–C is nor-
malized to the mock transfected group and combined from three independent
experiments. Statistical signiﬁcance was analyzed by two-tailed t-test: *po0.05
and **po0.005.
Fig. 6. The N-terminus of CypB is required for the enhancement of HIV infection.
(A) Infection experiments were performed as described in legend of Fig. 1 using
indicated deletion mutants and a PPI inactive mutant. Results shown were nor-
malized to cells transfected with empty vector control and are representative of a
minimum of three replicate experiments. Asterisks indicated signiﬁcant difference
in infection compared to cells transfected with wild-type CypB (*po0.001 by two-
tailed t-test). At the end of each experiment the expression of each mutant was
veriﬁed by FLAG immunoblot of cell lysates (bottom panels). (B) Overall cell via-
bility following expression of CypB and each mutant was monitored by MTT assay.
J. DeBoer et al. / Virology 489 (2016) 282–291286to enhance HIV infection (Δ10, Δ33, and Δ40) also failed to form
perinuclear foci.
We also looked at the localization of the CypB mutants by cell
fractionation and immunoblotting (Fig. 8). 293T cells expressing thetagged CypB mutants were fractionated into cytoplasmic, membrane/
organelle, nuclear and insoluble/cytoskeletal fractions. Fraction con-
sistency was again monitored by detection of various subcellular
markers (Fig. 8, bottom blots). Wild-type CypB was observed in the
cytoplasmic, membrane/organelle, as nuclear fractions consistent
with our immunoﬂuorescence data and previous reports (Price et al.,
1994). Several isoforms of CypB were detected in the membrane
fractions. The mature form of CypB in cells lacks the N-terminal
leader sequence with removal of the ﬁrst 32 amino acids and
migrates at approximately 18–20 kDa (Spik et al., 1991). The mature
form of the FLAG-tagged protein migrates at approximately 23–
24 kDa The larger band likely represented either the full length “pro”
form of CypB or the mature form with a modiﬁcation (consistent
with this idea, WT, Δ5, Δ10, and Δ33 all migrate at a similar size
(Fig. 6)). Interestingly, only the mature form of CypB was detected in
the cytoplasm of cells and conversely, only larger isoforms of WT
CypB were detected in nuclei. Both the Δ5 and Δ10 mutants frac-
tionated similar to WT CypB with the notable exception that the
mature isoforms were detected in nuclei instead of the larger forms.
Consistent with the IFA data as well as the removal of the ER leader
sequences, both Δ33 and Δ40 were detected in the cytoplasmic
fractions only. The Δ206 mutant was present in the cytoplasmic,
organelle, and nuclear fractions but as expected with the deletion of
the C-terminal ER retention signal (Arber et al., 1992), it exhibited a
higher proportion of cytoplasmic to membrane localization com-
pared to WT CypB. Notably, three isoforms of Δ206 were observed,
conﬁrming that any modiﬁcation, if present, was not in the C-
terminus of CypB. Finally, the PPIm showed a localization distribu-
tion similar to Δ206, with a higher proportion in the cytoplasmic
fractions of cells. Overall, these results show that the N-terminal
truncation of CypB caused aberrant localization and expression of the
CypB isoforms. Thus, the CypB mutants that lost the ability to
Fig. 7. The intracellular localization of the CypB deletion mutants. HeLa cells were transfected with CypB or indicated mutant expression vectors. After 24 h the cells were
ﬁxed, permeabilized and protein localization detected by immunoﬂuorescence using a FITC conjugated anti-FLAG antibody. Nuclei were stained with DAPI. Panels are
representative images of the localization of each protein as observed in two independent experiments.
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pared to wild-type CypB.
Secreted CypB does not enhance HIV infection
CypB is secreted from cells through the ER pathway and found
in milk and blood (Mariller et al., 1996). Therefore we surmised
that deletion of the N-terminus of CypB would block secretion of
the protein. Since all the enhancement-null mutants displayed
changes in their intracellular localization, we next tested if the
secretion of CypB was necessary for the enhancement of HIV
infection. First we assessed the secretion of each mutant by
immunoblot (Fig. 9A). Only the PPI mutant was detected in
supernatants at a level equivalent to wild-type CypB. Importantly,
the loss of secretion of the Δ206 mutant suggested that the
secretion of CypB was not critical for its ability to enhance infec-
tion as it potentiated infection as well as WT CypB. To further test
if extracellular CypB was involved in the enhancement of infection,
we performed media transfer experiments in which cells were
infected with virus pre-mixed 1:1 with media from cells over-
expressing CypB, CypA, or mock transfected cells. Both CypB and
CypA could be detected in the media from transfected cells
(Fig. 9B, top blot). Trans-addition of the media from CypB over-
expressing cells to target cells only slightly enhanced HIV infec-
tion, and no effect was seen with the CypA media (Fig. 9B, graph).
Notably, we did not observe any uptake of either CypB or CypA
into the recipient cells (Fig. 9B, bottom blot, 2° lanes). We con-
cluded from these results that secreted CypB does not play a
principal role in the enhancement of HIV infection.CypB potentiation does not involve the STAT5 pathway
Previous reports suggest that CypB is a chaperone for the
nuclear localization of IRF-3 and prolactin (Obata et al., 2005;
Rycyzyn et al., 2000), suggesting it interacts with a nuclear import
pathway. In the nucleus, the CypB-prolactin complex interacts
with and activates the Stat5 transcription factor (Rycyzyn and
Clevenger, 2002). A single report previously indicated that ectopic
expression of Stat5 increases HIV-1 expression in primary T-cells
(Selliah et al., 2006). To determine if Stat5 activation was necessary
for CypB potentiation, we tested whether over-expression of CypB
would enhance HIV infection in the presence of the commercially
available Stat5 inhibitor N0-((4-Oxo-4H-chromen-3-yl)methylene)
nicotinohydrazide. At odds with the ﬁndings of the previous
report, we observed that treatment with the inhibitor increased
HIV infection in a dose-dependent manner (Fig. 10A). Importantly
for our studies, the over-expression of CypB still potentiated
infection at all treatment levels. Stat5 did not appear to alter cell
metabolism as measured by MTT assay (Fig. 10B), but did cause a
decrease in DNA synthesis as evidenced by few cells in S and G2
phases of the cell cycle (Fig. 10C). These results coupled with the
fact that 1) deletion of the 40 N-terminal amino acids of CypB
retains prolactin binding (Rycyzyn et al., 2000), but blocks nuclear
import of prolactin; and 2) mutation of the PPI domain of CypB,
which still enhances HIV infection, does not activate Stat5
(Rycyzyn and Clevenger, 2002), lead us to conclude that the
enhancement effect of CypB is independent of Stat5 activation and
involves a novel mechanism.
Fig. 8. The subcellular distribution of the CypB deletion mutants. 293T cells
transfected with CypB or indicated mutant were fractionated into cytosolic (Cyt),
membrane/organelle (Mem), nuclear (Nu), and cytoskeletal/insoluble (In) sub-
cellular fractions. Fractions were separated by SDS-PAGE and immunoblotted with
anti-FLAG antibodies. Bottom three panels show control immunoblots for cell
fractionation. Results shown are representative of two independent experiments.
Fig. 9. Secreted CypB does not enhance HIV infection in trans. (A) Secretion of CypB
mutants. Cells were transfected with CypB or indicated mutants. After 24 h
supernatants and cell lysates were collected and analyzed for protein expression by
immmunoblot. (B) Media transfer experiments. Donor 293T cells were transfected
with indicated expression constructs. At 24 h post-transfection the media was
changed to eliminate excess transfection complexes. After an additional 24 h
supernatants and cell lysates were collected. NLX-Luc virus stock was mixed 1:1
with donor supernatant and used to infected untransfected recipient cells. At 48
hpi recipient cells were harvested and infection levels measured by Luc assay. The
secretion of CypB and CypA was monitored by immunoblot of donor supernatants
(top blot) and the ectopic expression of both CypB and CypA (1°) as well as uptake
into recipient cells (2°) was monitored by immunoblotting with anti-FLAG anti-
bodies (bottom blots). Graphed data represents the compilation of two indepen-
dent experiments and blots are representative images.
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The results from these studies show that the over-expression of
CypB enhances the infection of HIV-1 by increasing nuclear import
of viral DNA and suggests that CypB supports or activates a
pathway of HIV nuclear import. Overall, the over-expression of
CypB signiﬁcantly enhanced infection at a magnitude comparable
to other HIV cell factors (Hoque et al., 2011; Maddon et al., 1986;
Pushkarsky et al., 2007), and the effect occurred in the presence of
endogenous CypB. Unfortunately, we were unable to assess the
necessity of CypB for HIV infection as we could not knock-down
CypB in 293T cells without cytopathic effects (data not shown).
Another limitation of these studies was that the functional
experiments were limited to ﬁbroblasts. Ongoing studies seek to
advance these observations in immune cells. However, previous
proteomic studies indicate that CypB is upregulated in HIV infec-
ted cells (DeBoer et al., 2014; Haverland et al., 2014). Moreover, on
global siRNA study identiﬁed CypB as an HIV dependency factor
(Brass et al., 2008). Combined, these observations suggested
strongly that CypB plays a role in HIV infection.
CypB is a multifunctional protein involved in collagen transport
and ﬁbril formation (Choi et al., 2009; Smith et al., 1995), prolactin
signaling (Rycyzyn and Clevenger, 2002; Rycyzyn et al., 2000), and
immunosuppression (Swanson et al., 1992). Although shown pre-
viously to bind Gag, the role of CypB in HIV replication has notbeen extensively studied, possibly because of its homology to
CypA and an assumption that it must function analogously. Indeed,
both CypA and CypB are inhibited by CsA and both bind Gag;
albeit, CypB at higher afﬁnity due to its hydrophobic N-terminus
(Franke et al., 1994). The enhancement of HIV-1 infection by CypB
was clearly distinct from CypA as over-expression of CypA did not
increase infection, and CsA treatment, which blocks CypA-Gag
binding and increases secretion of CypB, did not impact the ability
of intracellular CypB to potentiate infection.
Consistent with the concept that the mechanism of CypB
enhancement is distinct from that of CypA, the deletion mutant
studies demonstrated that the N-terminus of CypB is required for
the effect. Moreover, the Δ33 and Δ40 mutants modestly inhib-
ited HIV infection. Deletion of this region of CypB resulted in a loss
of perinuclear localization and extracellular secretion. However,
the media transfer experiments showed that CypB did not sub-
stantially enhance infection when provided in trans, indicating
that secreted CypB was not involved in potentiating HIV infection.
Moreover, CypB was not efﬁciently taken up by the recipient cells,
nor could we detect it binding to virions in immunoprecipitation
assays (data not shown). Finally, CsA treatment increased the
secretion of CypB (Price et al., 1994), but in our experiments it did
not substantially affect (either positively or negatively) the ability
of CypB to boost infection when overexpressed.
Combined, the conclusion we draw from these results is that
the intracellular CypB is responsible for the enhancement of
infection. The localization of CypB is dynamic, consistent with its
role as a chaperon for several proteins. The IFA and cell fractio-
nation data of the deletion mutants show that the perinuclear
localization of CypB correlates with its ability to potentiate HIV
infection. The non-enhancing Δ33 and Δ40 mutants showed a
loss of perinuclear localization by IFA and a loss of detectable
Fig. 10. CypB enhancement does not require Stat5 activity. (A) Infection assays.
293T cells were transfected with either pcDNA3.1 empty vector or CypB. The fol-
lowing day media was changed and the cells pre-treated with indicated con-
centrations of STAT5 inhibitor for 4 h prior to transduction with NLX-Luc. At 48 hpi
cells were lysed and assayed for Luc activity, which was normalized to protein total
protein concentration. Results are presented relative to infected control cells
treated with DMSO and statistical differences analyzed by two-tailed t-test
(**po0.0001 and *po0.05). (B) MTT assay of cells treated with Stat5 inhibitor.
(C) Cell cycle analysis of cells treated with 5, 50, or 200 mM Stat5 inhibitor.
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experiments of fractionated cells. The Δ10 N-terminal mutant lost
the ability to potentiate infection and showed less concentrated
perinuclear staining in cells, although the immunoblot analyses
showed it still could enter the nuclear compartment. Combined,the data suggests that perinuclear localization of CypB is necessary
for increasing HIV infection.
We theorize two possible mechanisms of CypB enhancement.
First, that CypB may interact with the viral capsid, RTC, or PIC and
facilitate interactions with cellular pathways to increase the
nuclear import of the vDNA. Alternatively, the over-expression of
CypB may activate one or more cellular pathways that boost
import of the vDNA. CypB has been shown to contribute to the
nuclear localization of IRF-3 and prolactin (Obata et al., 2005;
Rycyzyn et al., 2000), but the mechanism of CypB nuclear import
and its interactions with the nuclear transport machinery have yet
to be deﬁned. The protein contains a lysine rich region at amino
acids 36–45 suggestive of a “classical”-type NLS, and deletion of
this region ablates prolactin nuclear import. We did not mutate
this region alone, and cannot rule out that both the NLS and the N-
terminus are needed to support HIV nuclear import. Indeed, since
deletions N-terminal to the NLS ablated the ability of CypB to
increase infection, it may be that CypB interacts with HIV or a
cellular factor in its N-terminus. Another possibility is that CypB
facilitates infection through an interaction in the perinuclear
region. One previous report suggested that the ER-associated SET
DNA repair complex was crucial for HIV nuclear import by limiting
auto-integration of viral DNA prior to nuclear import (Yan et al.,
2009). In addition to high resolution studies of CypB localization,
further study of the interactions of CypB with the HIV RTC and PIC
as well as the nuclear transport machinery are needed to clarify
the role of CypB as a nuclear chaperon. Delineating the mechanism
through which CypB modulates HIV infection will further our
understanding of HIV replication and may provide a target for
novel therapeutics.Materials and methods
Plasmids
The C-terminal FLAG-tagged CypB and CypA ORFs were obtained
from Origene Technologies (Rockville, MD). The CypB ORF was
moved by PCR into the pTarget eukaryotic expression vector (Pro-
mega Corp., Madison WI USA), the backbone used for the deletion
mutant ORFs which were constructed and inserted by PCR muta-
genesis. The PPI mutant was constructed in pTarget by PCR-overlap
mutagenesis and contained the amino acid substitutions R96 to A96
and F101 to A101. The primers used for mutagenesis were designed
using NCBI Reference Sequence # NM000942.4; sequences are
available upon request.
Cell culture and virus preparation
Lymphocytes from seronegative human donors were purchased
from the Elutriation Core facility at the University of Nebraska
Medical Center. Cells were cultured in RPMI media supplemented
with 10% fetal bovine serum, 50 U/ml IL-2 (NIH AIDS Research and
Reference Reagent Program, Germantown, MD), 8 mM L-gluta-
mine, 100 U/ml penicillin, and 100 mg/ml streptomycin. Cells were
activated by the addition of 10 mg/ml PHA for 48 h. 293T and HeLa
cells were maintained in Dulbecco's modiﬁed eagle medium
(DMEM) supplemented with 10% fetal clone 3 (Hyclone, Logan,
UT), 8 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml strep-
tomycin. Viruses were produced by transient transfection of 293T
cells using PolyJet reagent following the manufacturer's instruc-
tions (SignaGen Laboratories, Gaithersburg, MD). Brieﬂy, cells were
seeded into 10 cm dishes at 70% conﬂuency one day prior to
transfection. NLX virus was produced by transfecting 5 mg of pNLX
molecular clone (Brown et al., 1999); NLXLuc-VSVg virus was
produced by transfecting 3.5 μg of viral molecular clone (pNLX-luc)
J. DeBoer et al. / Virology 489 (2016) 282–291290DNA and 1.5 μg of pMD2.G vesicular stomatitis virus glycoprotein
G (VSVg) expression vector (Addgene Plasmid Repository, Cam-
bridge, MA). Media was collected at 24 and 48 h posttransduction
and clariﬁed by centrifugation at 4000 xg for 5 min. MLV-luc
viruses were produced following the same protocol using 2.5 μg
viral molecular clone (pFB-luc), 1.5 μg packaging vector (pCG-gag-
pol), and 1 μg pMD2.G. NLX virus was tittered on HeLa T4.β-gal
cells (NIH AIDS Repository) and VSVg-pseudotyped viruses were
titered on 293T cells. A TCID50 used for all infection experiments.
Infection assays
For lymphocyte infections, 2107 cells were infected for 6 h,
washed and maintained in IL-2 containing media. Virus replication
was monitored by sampling supernatants and measuring exogenous
reverse transcriptase activity as described previously (Belshan et al.,
2009). For 293 T transduction assays, 2105 cells were seeded in
triplicate wells of a 6-well plate. The following day each well was
transfected with a total of 500 ng plasmid using PolyJet transfection
reagent. For experiments showing a range of transfection, expression
plasmids were supplemented with empty vector control plasmids to
a total 500 ng. The next day, wells were inoculated with 100 ml of
HIV-luc or MLV-luc and incubated for 48 h at 37 °C. In indicated
experiments, CsAwas added 2 h prior to infection. Cells were lysed in
300 ml M-PER solution (Pierce Biotechnology, Rockford, IL) and clar-
iﬁed by centrifugation. Luciferase activity was determined using
One-glo luciferase reagent (Promega, Madison, WI) and measured
using a Spectramax L (Molecular Devices, Sunnyvale, CA). Protein
concentrations were determined by BCA protein assay (Thermo Sci-
entiﬁc, Rockford, IL) and used to normalize the amount of luciferase
activity in each sample. Subcellular compartments (cytosol, mem-
brane/organelle, nuclear, and cytoskeleton/insoluble) were isolated
using the Qproteome Cell Compartment kit as described by the
manufacturer (Qiagen, Valencia, CA). MTT assays were performed on
transfected cells using the CellTiter 96 non-radioactive cell
proliferation assay according to the manufacturer's speciﬁcations
(Promega, Madison, WI).
Immunoblotting
Samples were normalized by protein concentration with PBS,
mixed 1:1 with 2 SDS-PAGE loading buffer, boiled for 10 min,
separated by SDS-PAGE, and transferred to PVDF. Proteins were
detected by western blot using the following primary antibodies:
Anti-CypA (C-14), anti-CypB (k2E2), anti-ERGIC (H-245), anti-actin
(C4), and anti-GAPDH (6C5) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA); and anti-Topo IIa was from BD
Biosciences (San Jose, CA). The HRP-conjugated anti-Flag (M2)
antibody was from Sigma-Aldrich (St Louis, MO). HRP-conjugated
anti-rabbit and anti-mouse IgG secondary antibodies were also
from Santa Cruz Biotechnology. Antibody binding was detected and
visualized by West Pico chemiluminescent staining (Thermo
Scientiﬁc, Rockford, IL). Images were captured by exposure to
radiographic ﬁlm, scanned to computer, adjusted for brightness and
contrast if necessary, and cropped for size.
Indirect immunoﬂuorescence
HeLa cells were plated on sterile coverslips in a six-well plate at
50% conﬂuence. The following day, cells were transfected with CypB
expression plasmids and incubated overnight. Cells were washed
with PBS and ﬁxed for 5 min by addition of 2 ml 4% paraformalde-
hyde (w/v in PBS). Cells were permeabilized using 2 ml of 0.2% Triton
X-100 in PBS for 5 min. CypB proteins were detected with FITC
conjugated anti-Flag (M2) antibody diluted 1:1000 in PBSþ1% FBS;
2 ml was added to cells at 37 °C for 60 min. Cells were washed 3with PBSþ1% FBS and coverslips mounted onto slides with ProLongs
Gold antifade reagent with DAPI (Life Technologies, Eugene, OR).
Slides were dried overnight and imaged using a Nikon Eclipse Ci
microscope (Nikon USA, Melville, NY) and images captured using
Inﬁnity Analyze software (Lumenera, Ottawa, ON).
Quantiﬁcation of viral DNA species
293T cells were seeded into 6 well plates to achieve 50% con-
ﬂuence the following day. Cells were transfected with empty
control vector, CypB, or Δ40 and incubated overnight. NLXþVSVg
stocks were treated with 2 U/ml Turbo DNase (Ambion, Austin TX)
for 1 h at 37 °C prior to inoculation. Heat inactivated virus (30 min
at 65 °C) was also used as a negative control for each experiment.
Extra-chromosomal DNA was isolated at indicated times using the
modiﬁed HIRT protocol (Arad, 1998; Belshan et al., 2009). In all
experiments DNA was quantiﬁed by real-time PCR using a CFX
Connect real-time PCR detection system (Bio-Rad) with Bullseye
EvaGreen qPCR Master Mix (Midsci, Valley Park MO). Late reverse
transcription (LRT) viral DNA was quantiﬁed using gag-speciﬁc
primers NL919 (50-TTCGCAGTTAATCCTGGACTT-30) and NL1054 (50-
GCACACAATAGAGGACTGCTATTGTA). LRT was normalized to
detection of mitochondrial DNA, which was quantiﬁed using pri-
mers MitoFor (50-ACCCACTCCCTCTTAGCCAATATT-30) and MitoRev
(50-GTAGGGCTAGGCCCACCG-30). 2-LTR circles were quantiﬁed
using primers NL500 (50-AACTAGGGAACCCACTGCTTAAG-30) and
NL9126 (50-TCCACAGATCAAGGATATCTTGTC-30). These values were
normalized to the level of LRT viral DNA to account for variance in
infection. Chromosomal DNA was isolated using the EZNA Tissue
DNA Kit (Omega Biotek, Frederick CO) and integration was asses-
sed by nested Alu-PCR, using primers cNL658 (50-TTTCAG
GTCCCTGTTCGGGCGCCAC-30), Alu1 (TCCCAGCTACTGGGGAGGCT-
GAGG-30), and Alu2 (GCCTCCCAAAGTGCTGGGATTACAG-30) for the
initial PCR and primers NL493 (50-TCTGGCTAACTAGGGAACCCAC-
30) and cNL616 (50-CTGACTAAAAGGGTCTGAGG-30) for the second
PCR (Brussel and Sonigo, 2003). Integrated DNAwas normalized to
detection of β-globin intron DNA, which was quantiﬁed using
primers BGlobinFor (50-GCAAGAAAGTGCTCGGTGC-30) and BGlo-
binRev (50- CTACTCAGTGTGGCAAAG-30).
STAT5 inhibition assays
The STAT5 inhibitor (N0-((4-Oxo-4H-chromen-3-yl)methylene)
nicotinohydrazide) was obtained from Santa Cruz Biotechnology
and resuspended in DMSO to a concentration of 10 mg/ml. 293T
cells were seeded into 6 well plates to achieve 50–60% conﬂuence
the following day. Cells were pre-treated with STAT5 inhibitor for
4 h prior to transduction with NLX-Luc VSVg virus. At 24 h, virus
was removed and new media containing inhibitor added. At 48 h
post-transduction, cells were lysed with MPER and infection levels
measured as described above. For the both the MTT and cell cycle
analyses, 293T cells were pretreated with inhibitor for 24 h. For
cell cycle analysis, cells were harvested by centrifugation and
resuspended in Vindelov's reagent (10 mM Tris (pH 7.6), 10 μg/ml
RNase A, 75 μM propidium iodide, and 0.1% Igepal CA-630). Cells
were analyzed at the Creighton University ﬂow cytometry core
using a FACSAria ﬂow cytometer (BD Biosciences, San Jose, CA) and
Flowjo software (Treestar Inc., Ashland, OR).Acknowledgments
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